This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Naftopidil
Accession Number
DB12092
Type
Small Molecule
Groups
Investigational
Description

Naftopidil has been investigated for the treatment of Disorder of Urinary Stent.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
R9PHW59SFN
CAS number
57149-07-2
Weight
Average: 392.499
Monoisotopic: 392.20999277
Chemical Formula
C24H28N2O3
InChI Key
HRRBJVNMSRJFHQ-UHFFFAOYSA-N
InChI
InChI=1S/C24H28N2O3/c1-28-24-11-5-4-10-22(24)26-15-13-25(14-16-26)17-20(27)18-29-23-12-6-8-19-7-2-3-9-21(19)23/h2-12,20,27H,13-18H2,1H3
IUPAC Name
1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-(naphthalen-1-yloxy)propan-2-ol
SMILES
COC1=CC=CC=C1N1CCN(CC(O)COC2=CC=CC3=CC=CC=C23)CC1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(R)-warfarinThe risk or severity of bleeding can be increased when Naftopidil is combined with (R)-warfarin.Experimental
(S)-WarfarinThe risk or severity of bleeding can be increased when Naftopidil is combined with (S)-Warfarin.Experimental, Investigational
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Naftopidil is combined with 4-hydroxycoumarin.Experimental
AbafunginThe therapeutic efficacy of Abafungin can be increased when used in combination with Naftopidil.Investigational
AbciximabNaftopidil may increase the anticoagulant activities of Abciximab.Approved
AcebutololAcebutolol may increase the hypotensive activities of Naftopidil.Approved, Investigational
AceclofenacThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolThe risk or severity of bleeding can be increased when Naftopidil is combined with Acenocoumarol.Approved, Investigational
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Naftopidil.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Naftopidil is combined with Acetylsalicylic acid.Approved, Vet Approved
AlaproclateAlaproclate may increase the antiplatelet activities of Naftopidil.Experimental
AlbaconazoleThe therapeutic efficacy of Albaconazole can be increased when used in combination with Naftopidil.Investigational
AlclofenacThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlcuroniumNaftopidil may increase the neuromuscular blocking activities of Alcuronium.Experimental
AlfuzosinAlfuzosin may increase the hypotensive activities of Naftopidil.Approved, Investigational
AliskirenAliskiren may increase the hypotensive activities of Naftopidil.Approved, Investigational
AlminoprofenThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Alminoprofen.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Naftopidil is combined with Aloxiprin.Experimental
AlprenololNaftopidil may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AlteplaseNaftopidil may increase the anticoagulant activities of Alteplase.Approved
AmbrisentanNaftopidil may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmediplaseNaftopidil may increase the anticoagulant activities of Amediplase.Investigational
AmifostineNaftopidil may increase the hypotensive activities of Amifostine.Approved, Investigational
AminophenazoneThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Aminophenazone.Approved, Withdrawn
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Naftopidil is combined with Aminosalicylic Acid.Approved
AmiodaroneThe metabolism of Naftopidil can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe risk or severity of hypotension can be increased when Amitriptyline is combined with Naftopidil.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Naftopidil.Approved
AmobarbitalThe metabolism of Naftopidil can be increased when combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of hypotension can be increased when Amoxapine is combined with Naftopidil.Approved
Amphotericin BNaftopidil may decrease the nephrotoxic activities of Amphotericin B.Approved, Investigational
AmprenavirThe metabolism of Naftopidil can be decreased when combined with Amprenavir.Approved, Investigational
AnagrelideNaftopidil may increase the anticoagulant activities of Anagrelide.Approved
AncrodNaftopidil may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideAndrographolide may increase the antiplatelet activities of Naftopidil.Investigational
AnistreplaseNaftopidil may increase the anticoagulant activities of Anistreplase.Approved
AntipyrineThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Antipyrine.Approved, Investigational
Antithrombin III humanThe risk or severity of bleeding can be increased when Naftopidil is combined with Antithrombin III human.Approved
AntrafenineThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Antrafenine.Approved
ApalutamideThe serum concentration of Naftopidil can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe risk or severity of adverse effects can be increased when Naftopidil is combined with Apixaban.Approved
AprepitantThe serum concentration of Naftopidil can be increased when it is combined with Aprepitant.Approved, Investigational
ArdeparinThe risk or severity of bleeding can be increased when Naftopidil is combined with Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanNaftopidil may increase the anticoagulant activities of Argatroban.Approved, Investigational
AripiprazoleThe risk or severity of hypotension can be increased when Aripiprazole is combined with Naftopidil.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Naftopidil.Approved, Investigational
ArotinololThe risk or severity of hypotension can be increased when Arotinolol is combined with Naftopidil.Investigational
AsenapineThe risk or severity of hypotension can be increased when Asenapine is combined with Naftopidil.Approved
AstaxanthinNaftopidil may increase the anticoagulant activities of Astaxanthin.Investigational
AtazanavirThe metabolism of Naftopidil can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Naftopidil.Approved
AtracuriumNaftopidil may increase the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateNaftopidil may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AvanafilAvanafil may increase the antihypertensive activities of Naftopidil.Approved
AzapropazoneThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Azapropazone.Withdrawn
BalsalazideThe risk or severity of adverse effects can be increased when Naftopidil is combined with Balsalazide.Approved, Investigational
BarbexacloneThe metabolism of Naftopidil can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Naftopidil can be increased when combined with Barbital.Illicit
BarnidipineNaftopidil may increase the antihypertensive activities of Barnidipine.Approved
BemiparinThe risk or severity of bleeding can be increased when Naftopidil is combined with Bemiparin.Approved, Investigational
BenazeprilBenazepril may increase the hypotensive activities of Naftopidil.Approved, Investigational
BenazeprilatNaftopidil may increase the hypotensive activities of Benazeprilat.Experimental
BendazacThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Bendazac.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Naftopidil.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Naftopidil.Withdrawn
BenorilateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzydamineThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Benzydamine.Approved
BepridilBepridil may increase the hypotensive activities of Naftopidil.Approved, Withdrawn
BeraprostBeraprost may increase the antiplatelet activities of Naftopidil.Investigational
BetaxololBetaxolol may increase the hypotensive activities of Naftopidil.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Naftopidil.Approved
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Naftopidil.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Naftopidil.Experimental
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Naftopidil.Approved, Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Naftopidil.Approved, Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Naftopidil.Approved
BisoprololBisoprolol may increase the hypotensive activities of Naftopidil.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Naftopidil.Approved
BivalirudinThe risk or severity of bleeding can be increased when Naftopidil is combined with Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Naftopidil can be decreased when combined with Boceprevir.Approved, Withdrawn
BosentanThe serum concentration of Naftopidil can be decreased when it is combined with Bosentan.Approved, Investigational
BQ-123BQ-123 may increase the hypotensive activities of Naftopidil.Investigational
BretyliumBretylium may increase the hypotensive activities of Naftopidil.Approved
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Naftopidil.Approved, Investigational
BrinaseNaftopidil may increase the anticoagulant activities of Brinase.Experimental
BromfenacThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe risk or severity of hypotension can be increased when Bromocriptine is combined with Naftopidil.Approved, Investigational
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Naftopidil.Investigational
BufexamacThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Bufexamac.Approved, Experimental
BuflomedilNaftopidil may increase the antiplatelet activities of Buflomedil.Experimental
BumadizoneThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Bumadizone.Experimental
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Naftopidil.Investigational
BupranololNaftopidil may increase the hypotensive activities of Bupranolol.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Naftopidil.Approved
ButylphthalideNaftopidil may increase the antiplatelet activities of Butylphthalide.Investigational
CadralazineCadralazine may increase the hypotensive activities of Naftopidil.Experimental
Calcium AcetateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium Phosphate.Approved
CandesartanNaftopidil may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Naftopidil.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Naftopidil.Experimental
CangrelorCangrelor may increase the antiplatelet activities of Naftopidil.Approved
CaptoprilCaptopril may increase the hypotensive activities of Naftopidil.Approved
CarbamazepineThe metabolism of Naftopidil can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Naftopidil is combined with Carbaspirin calcium.Experimental, Investigational
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Naftopidil.Approved, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Naftopidil.Withdrawn
CarprofenThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololNaftopidil may increase the hypotensive activities of Carteolol.Approved
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Naftopidil.Approved, Investigational
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Naftopidil.Approved, Investigational, Nutraceutical, Vet Approved
CelecoxibThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Naftopidil.Approved, Investigational
CeritinibThe serum concentration of Naftopidil can be increased when it is combined with Ceritinib.Approved
CertoparinThe risk or severity of bleeding can be increased when Naftopidil is combined with Certoparin.Approved, Investigational
ChlorothiazideChlorothiazide may increase the hypotensive activities of Naftopidil.Approved, Vet Approved
ChlorpromazineThe risk or severity of hypotension can be increased when Chlorpromazine is combined with Naftopidil.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Naftopidil.Approved
Choline magnesium trisalicylateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CicletanineNaftopidil may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilCilazapril may increase the hypotensive activities of Naftopidil.Approved
CilostazolCilostazol may increase the antiplatelet activities of Naftopidil.Approved, Investigational
CimetidineThe serum concentration of Naftopidil can be increased when it is combined with Cimetidine.Approved, Investigational
CimicoxibThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Cimicoxib.Investigational
CisatracuriumNaftopidil may increase the neuromuscular blocking activities of Cisatracurium.Approved
CitalopramCitalopram may increase the antiplatelet activities of Naftopidil.Approved
ClarithromycinThe metabolism of Naftopidil can be decreased when combined with Clarithromycin.Approved
ClonidineClonidine may increase the hypotensive activities of Naftopidil.Approved
ClonixinThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Clonixin.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Naftopidil.Approved
CloranololNaftopidil may increase the hypotensive activities of Cloranolol.Experimental
CloricromenNaftopidil may increase the antiplatelet activities of Cloricromen.Experimental
ClorindioneThe risk or severity of bleeding can be increased when Naftopidil is combined with Clorindione.Experimental
ClotrimazoleThe metabolism of Naftopidil can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of hypotension can be increased when Clozapine is combined with Naftopidil.Approved
CobicistatThe metabolism of Naftopidil can be decreased when combined with Cobicistat.Approved
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Naftopidil is combined with Collagenase clostridium histolyticum.Approved, Investigational
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Naftopidil.Approved, Investigational
CrizotinibThe metabolism of Naftopidil can be decreased when combined with Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Naftopidil.Approved
CurcuminThe metabolism of Naftopidil can be decreased when combined with Curcumin.Approved, Investigational
CyclopenthiazideNaftopidil may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Naftopidil can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Naftopidil.Approved
Dabigatran etexilateNaftopidil may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Naftopidil can be decreased when it is combined with Dabrafenib.Approved, Investigational
DalteparinNaftopidil may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidNaftopidil may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DanazolThe metabolism of Naftopidil can be decreased when combined with Danazol.Approved
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Naftopidil.Approved, Investigational, Withdrawn
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Naftopidil.Approved
DapoxetineDapoxetine may increase the antiplatelet activities of Naftopidil.Investigational
DarexabanThe risk or severity of bleeding can be increased when Naftopidil is combined with Darexaban.Investigational
DarunavirThe metabolism of Naftopidil can be decreased when combined with Darunavir.Approved
DasatinibDasatinib may increase the anticoagulant activities of Naftopidil.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Naftopidil.Approved, Investigational
DeferasiroxThe serum concentration of Naftopidil can be decreased when it is combined with Deferasirox.Approved, Investigational
DefibrotideNaftopidil may increase the anticoagulant activities of Defibrotide.Approved, Investigational
DelaprilNaftopidil may increase the hypotensive activities of Delapril.Investigational
DelavirdineThe metabolism of Naftopidil can be decreased when combined with Delavirdine.Approved
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Naftopidil is combined with Deoxycholic Acid.Approved
DersalazineThe risk or severity of adverse effects can be increased when Naftopidil is combined with Dersalazine.Investigational
DeserpidineNaftopidil may increase the hypotensive activities of Deserpidine.Approved
DesirudinThe risk or severity of bleeding can be increased when Naftopidil is combined with Desirudin.Approved
DesmoteplaseNaftopidil may increase the anticoagulant activities of Desmoteplase.Investigational
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Naftopidil.Approved, Investigational
DexamethasoneThe serum concentration of Naftopidil can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexibuprofenThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Dexibuprofen.Approved, Investigational
DexketoprofenThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Dexketoprofen.Approved, Investigational
DexniguldipineNaftopidil may increase the hypotensive activities of Dexniguldipine.Experimental
DextranThe risk or severity of bleeding can be increased when Naftopidil is combined with Dextran.Approved, Investigational, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Naftopidil.Approved
DiclofenacThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DicoumarolNaftopidil may increase the anticoagulant activities of Dicoumarol.Approved
DiethylnorspermineDiethylnorspermine may increase the hypotensive activities of Naftopidil.Investigational
DifenpiramideThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Difenpiramide.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Naftopidil is combined with Diflunisal.Approved, Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Naftopidil.Approved, Investigational
DihydroergotamineThe risk or severity of hypotension can be increased when Dihydroergotamine is combined with Naftopidil.Approved, Investigational
DiltiazemThe metabolism of Naftopidil can be decreased when combined with Diltiazem.Approved, Investigational
DiphenadioneThe risk or severity of bleeding can be increased when Naftopidil is combined with Diphenadione.Experimental
DipyridamoleDipyridamole may increase the antihypertensive activities of Naftopidil.Approved
DitazoleThe risk or severity of bleeding can be increased when Naftopidil is combined with Ditazole.Approved, Withdrawn
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Naftopidil.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Naftopidil.Approved
DoxacuriumNaftopidil may increase the neuromuscular blocking activities of Doxacurium.Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Naftopidil.Approved
DoxepinThe risk or severity of hypotension can be increased when Doxepin is combined with Naftopidil.Approved, Investigational
DoxycyclineThe metabolism of Naftopidil can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe risk or severity of hypotension can be increased when Dronedarone is combined with Naftopidil.Approved
DroperidolThe risk or severity of hypotension can be increased when Droperidol is combined with Naftopidil.Approved, Vet Approved
Drotrecogin alfaNaftopidil may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Droxicam.Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Naftopidil.Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Naftopidil.Approved
Edetic AcidThe risk or severity of bleeding can be increased when Naftopidil is combined with Edetic Acid.Approved, Vet Approved
EdoxabanThe risk or severity of bleeding can be increased when Naftopidil is combined with Edoxaban.Approved
EfavirenzThe serum concentration of Naftopidil can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Naftopidil.Approved
EfonidipineEfonidipine may increase the hypotensive activities of Naftopidil.Approved, Investigational
EnalaprilEnalapril may increase the hypotensive activities of Naftopidil.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the hypotensive activities of Naftopidil.Approved
EndralazineEndralazine may increase the hypotensive activities of Naftopidil.Experimental
EnoxaparinThe risk or severity of bleeding can be increased when Naftopidil is combined with Enoxaparin.Approved
EnzalutamideThe serum concentration of Naftopidil can be decreased when it is combined with Enzalutamide.Approved
EpanololNaftopidil may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Epirizole.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Naftopidil.Approved
EprosartanEprosartan may increase the hypotensive activities of Naftopidil.Approved
EptifibatideEptifibatide may increase the antiplatelet activities of Naftopidil.Approved, Investigational
ErgotamineThe risk or severity of hypotension can be increased when Ergotamine is combined with Naftopidil.Approved
ErythromycinThe metabolism of Naftopidil can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololNaftopidil may increase the hypotensive activities of Esatenolol.Experimental
EscitalopramEscitalopram may increase the antiplatelet activities of Naftopidil.Approved, Investigational
EsmololNaftopidil may increase the hypotensive activities of Esmolol.Approved
EthenzamideThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Ethenzamide.Experimental
Ethyl biscoumacetateThe risk or severity of bleeding can be increased when Naftopidil is combined with Ethyl biscoumacetate.Withdrawn
EtodolacThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Etofenamate.Approved, Investigational
EtoricoxibThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Naftopidil can be decreased when it is combined with Etravirine.Approved
FelbinacThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Felbinac.Experimental
FelodipineFelodipine may increase the hypotensive activities of Naftopidil.Approved, Investigational
FenbufenThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Naftopidil.Approved
FenoprofenThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Fenoprofen.Approved
FentiazacThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Fentiazac.Experimental
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Naftopidil.Experimental
FeprazoneThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Feprazone.Experimental
Ferulic acidFerulic acid may increase the hypotensive activities of Naftopidil.Experimental
FibrinolysinNaftopidil may increase the anticoagulant activities of Fibrinolysin.Investigational
FirocoxibThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Firocoxib.Experimental, Vet Approved
FloctafenineThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Floctafenine.Approved, Withdrawn
FluconazoleThe metabolism of Naftopidil can be decreased when combined with Fluconazole.Approved, Investigational
FluindioneThe risk or severity of bleeding can be increased when Naftopidil is combined with Fluindione.Approved, Investigational
FlunixinThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Flunoxaprofen.Experimental
FluoxetineFluoxetine may increase the antiplatelet activities of Naftopidil.Approved, Vet Approved
FlupentixolThe risk or severity of hypotension can be increased when Flupentixol is combined with Naftopidil.Approved, Investigational, Withdrawn
FlurbiprofenThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Naftopidil.Experimental
FluvoxamineFluvoxamine may increase the antiplatelet activities of Naftopidil.Approved, Investigational
FondaparinuxNaftopidil may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
FosamprenavirThe metabolism of Naftopidil can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Naftopidil can be increased when it is combined with Fosaprepitant.Approved
FosinoprilFosinopril may increase the hypotensive activities of Naftopidil.Approved
FosinoprilatNaftopidil may increase the hypotensive activities of Fosinoprilat.Experimental
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Naftopidil.Approved, Investigational
FostamatinibFostamatinib may increase the antihypertensive activities of Naftopidil.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Naftopidil.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Naftopidil can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabexateThe risk or severity of bleeding can be increased when Naftopidil is combined with Gabexate.Investigational
GallamineNaftopidil may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideNaftopidil may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GlucosamineGlucosamine may increase the antiplatelet activities of Naftopidil.Approved, Investigational
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Naftopidil.Approved, Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Naftopidil is combined with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Naftopidil.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Naftopidil.Approved
GuanazodineNaftopidil may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Naftopidil.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Naftopidil.Approved, Investigational
GuanoclorNaftopidil may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzNaftopidil may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanNaftopidil may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Naftopidil.Experimental
HeparinThe risk or severity of bleeding can be increased when Naftopidil is combined with Heparin.Approved, Investigational
HexamethoniumHexamethonium may increase the hypotensive activities of Naftopidil.Experimental
HexobarbitalThe metabolism of Naftopidil can be increased when combined with Hexobarbital.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Naftopidil.Experimental
HydralazineHydralazine may increase the hypotensive activities of Naftopidil.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Naftopidil.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Naftopidil.Approved, Investigational
HydroxytyrosolNaftopidil may increase the antiplatelet activities of Hydroxytyrosol.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Naftopidil is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Naftopidil.Approved
IbudilastIbudilast may increase the antiplatelet activities of Naftopidil.Approved, Investigational
IbuprofenThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Ibuproxam.Withdrawn
IcosapentThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Icosapent.Approved, Nutraceutical
Icosapent ethylIcosapent ethyl may increase the antiplatelet activities of Naftopidil.Approved, Investigational, Nutraceutical
IdelalisibThe metabolism of Naftopidil can be decreased when combined with Idelalisib.Approved
IdraparinuxThe risk or severity of bleeding can be increased when Naftopidil is combined with Idraparinux.Investigational
IfetrobanNaftopidil may increase the antiplatelet activities of Ifetroban.Investigational
IloperidoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Naftopidil.Approved
IloprostIloprost may increase the hypotensive activities of Naftopidil.Approved, Investigational
ImatinibThe metabolism of Naftopidil can be decreased when combined with Imatinib.Approved
ImidaprilImidapril may increase the hypotensive activities of Naftopidil.Investigational
Imidazole salicylateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Imidazole salicylate.Experimental
ImipramineThe risk or severity of hypotension can be increased when Imipramine is combined with Naftopidil.Approved
IndalpineIndalpine may increase the antiplatelet activities of Naftopidil.Investigational, Withdrawn
IndapamideIndapamide may increase the hypotensive activities of Naftopidil.Approved
IndenololIndenolol may increase the hypotensive activities of Naftopidil.Withdrawn
IndinavirThe metabolism of Naftopidil can be decreased when combined with Indinavir.Approved
IndobufenNaftopidil may increase the antiplatelet activities of Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Naftopidil.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Naftopidil.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Naftopidil.Approved, Investigational
IsavuconazoleThe serum concentration of Naftopidil can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Naftopidil can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Naftopidil.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Naftopidil.Approved
IsoniazidThe metabolism of Naftopidil can be decreased when combined with Isoniazid.Approved, Investigational
IsoxicamThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Isoxicam.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Naftopidil.Approved, Investigational
ItraconazoleThe metabolism of Naftopidil can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Naftopidil can be increased when it is combined with Ivacaftor.Approved
KebuzoneThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Kebuzone.Experimental
KetanserinNaftopidil may increase the antiplatelet activities of Ketanserin.Investigational
KetoconazoleThe metabolism of Naftopidil can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Ketorolac.Approved
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Naftopidil.Approved
LacidipineLacidipine may increase the hypotensive activities of Naftopidil.Approved, Investigational
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Naftopidil.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Naftopidil.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Naftopidil.Approved, Investigational
LepirudinThe risk or severity of bleeding can be increased when Naftopidil is combined with Lepirudin.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Naftopidil.Approved, Investigational
LetaxabanThe risk or severity of bleeding can be increased when Naftopidil is combined with Letaxaban.Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Naftopidil.Approved, Investigational
LimaprostLimaprost may increase the antiplatelet activities of Naftopidil.Approved, Investigational
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Naftopidil.Approved
LinezolidLinezolid may increase the hypotensive activities of Naftopidil.Approved, Investigational
LinsidomineNaftopidil may increase the antiplatelet activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Naftopidil.Approved, Investigational
LofexidineLofexidine may increase the hypotensive activities of Naftopidil.Approved, Investigational
LonazolacThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Lonazolac.Experimental
LopinavirThe metabolism of Naftopidil can be decreased when combined with Lopinavir.Approved
LornoxicamThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Lornoxicam.Approved, Investigational
LorpiprazoleThe serum concentration of Naftopidil can be increased when it is combined with Lorpiprazole.Approved
LosartanLosartan may increase the hypotensive activities of Naftopidil.Approved
LovastatinThe metabolism of Naftopidil can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Naftopidil.Approved, Investigational
LuliconazoleThe serum concentration of Naftopidil can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Naftopidil can be increased when combined with Lumacaftor.Approved
LumiracoxibThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Lumiracoxib.Approved, Investigational
MacitentanNaftopidil may increase the hypotensive activities of Macitentan.Approved
Magnesium carbonateThe therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Naftopidil.Approved, Investigational
Magnesium citrateThe therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Naftopidil.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Naftopidil is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Naftopidil is combined with Magnesium oxide.Approved
Magnesium peroxideThe therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Naftopidil.Experimental
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Naftopidil is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Naftopidil is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineManidipine may increase the hypotensive activities of Naftopidil.Approved, Investigational
MannitolThe therapeutic efficacy of Mannitol can be decreased when used in combination with Naftopidil.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Naftopidil.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Naftopidil.Approved, Investigational
Meclofenamic acidThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Mefenamic acid.Approved
MelagatranThe risk or severity of bleeding can be increased when Naftopidil is combined with Melagatran.Experimental
MeloxicamThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Naftopidil is combined with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Metamizole.Approved, Investigational, Withdrawn
MethohexitalThe metabolism of Naftopidil can be increased when combined with Methohexital.Approved
MethoserpidineNaftopidil may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Naftopidil.Approved, Investigational
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Naftopidil.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Naftopidil is combined with Methyl salicylate.Approved, Vet Approved
MethyldopaMethyldopa may increase the hypotensive activities of Naftopidil.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Naftopidil.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Naftopidil.Approved, Investigational
MethylphenobarbitalThe metabolism of Naftopidil can be increased when combined with Methylphenobarbital.Approved
MetipranololMetipranolol may increase the hypotensive activities of Naftopidil.Approved
MetocurineNaftopidil may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideNaftopidil may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MetolazoneMetolazone may increase the hypotensive activities of Naftopidil.Approved
MetoprololMetoprolol may increase the hypotensive activities of Naftopidil.Approved, Investigational
MetyrosineNaftopidil may increase the hypotensive activities of Metyrosine.Approved
MibefradilThe metabolism of Naftopidil can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Naftopidil can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MifepristoneThe serum concentration of Naftopidil can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the antiplatelet activities of Naftopidil.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Naftopidil.Approved
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Naftopidil.Approved, Vet Approved
MinoxidilMinoxidil may increase the hypotensive activities of Naftopidil.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Naftopidil.Investigational
MitotaneThe serum concentration of Naftopidil can be decreased when it is combined with Mitotane.Approved
MivacuriumNaftopidil may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Naftopidil.Approved, Investigational
ModafinilThe serum concentration of Naftopidil can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Naftopidil.Approved
MofebutazoneThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Naftopidil.Approved, Investigational
MorniflumateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Morniflumate.Approved
MoxonidineMoxonidine may increase the hypotensive activities of Naftopidil.Approved, Investigational
MuzolimineNaftopidil may increase the hypotensive activities of Muzolimine.Experimental
NabumetoneThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Nabumetone.Approved
NadololNaftopidil may increase the hypotensive activities of Nadolol.Approved
NadroparinThe risk or severity of bleeding can be increased when Naftopidil is combined with Nadroparin.Approved, Investigational
NafamostatThe risk or severity of bleeding can be increased when Naftopidil is combined with Nafamostat.Approved, Investigational
NafcillinThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Nafcillin.Approved, Investigational
NaloxoneThe metabolism of Naftopidil can be decreased when combined with Naloxone.Approved, Vet Approved
NaproxenThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Naproxen.Approved, Vet Approved
NebivololNebivolol may increase the hypotensive activities of Naftopidil.Approved, Investigational
NefazodoneThe risk or severity of hypotension can be increased when Nefazodone is combined with Naftopidil.Approved, Withdrawn
NelfinavirThe metabolism of Naftopidil can be decreased when combined with Nelfinavir.Approved
NepafenacThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Nepafenac.Approved, Investigational
NetupitantThe serum concentration of Naftopidil can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Naftopidil can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Naftopidil.Withdrawn
NicardipineThe risk or severity of hypotension can be increased when Nicardipine is combined with Naftopidil.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Naftopidil.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Naftopidil.Approved, Investigational
NifenazoneThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Naftopidil.Experimental
NilotinibThe metabolism of Naftopidil can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineNilvadipine may increase the hypotensive activities of Naftopidil.Approved, Investigational
NimesulideNimesulide may increase the antiplatelet activities of Naftopidil.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Naftopidil.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Naftopidil.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Naftopidil.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Naftopidil is combined with Nitroaspirin.Investigational
NitroprussideNaftopidil may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NortriptylineThe risk or severity of hypotension can be increased when Nortriptyline is combined with Naftopidil.Approved
NS-398The therapeutic efficacy of Naftopidil can be decreased when used in combination with NS-398.Experimental
ObinutuzumabThe risk or severity of adverse effects can be increased when Naftopidil is combined with Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Naftopidil.Withdrawn
OlanzapineThe risk or severity of hypotension can be increased when Olanzapine is combined with Naftopidil.Approved, Investigational
OlaparibThe metabolism of Naftopidil can be decreased when combined with Olaparib.Approved
OlmesartanOlmesartan may increase the hypotensive activities of Naftopidil.Approved, Investigational
OlsalazineThe risk or severity of adverse effects can be increased when Naftopidil is combined with Olsalazine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Naftopidil.Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Naftopidil.Approved, Nutraceutical
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Naftopidil.Experimental
OsimertinibThe serum concentration of Naftopidil can be increased when it is combined with Osimertinib.Approved
OtamixabanThe risk or severity of bleeding can be increased when Naftopidil is combined with Otamixaban.Investigational
OxaprozinThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Oxaprozin.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Naftopidil.Approved
OxprenololNaftopidil may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Naftopidil.Investigational, Withdrawn
PalbociclibThe serum concentration of Naftopidil can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of hypotension can be increased when Paliperidone is combined with Naftopidil.Approved
PancuroniumNaftopidil may increase the neuromuscular blocking activities of Pancuronium.Approved
ParecoxibThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Naftopidil.Approved
ParnaparinThe risk or severity of bleeding can be increased when Naftopidil is combined with Parnaparin.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Naftopidil.Approved, Investigational
Patent BlueThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Patent Blue.Approved
PenbutololNaftopidil may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Naftopidil.Experimental
PentobarbitalThe metabolism of Naftopidil can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Naftopidil.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Naftopidil.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Naftopidil.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Naftopidil.Approved
PerindoprilatNaftopidil may increase the hypotensive activities of Perindoprilat.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Naftopidil.Approved
PhenindioneThe risk or severity of bleeding can be increased when Naftopidil is combined with Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the hypotensive activities of Naftopidil.Withdrawn
PhenobarbitalThe metabolism of Naftopidil can be increased when combined with Phenobarbital.Approved, Investigational
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Naftopidil.Approved, Withdrawn
PhenoxybenzamineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Naftopidil.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Naftopidil.Withdrawn
PhenprocoumonThe risk or severity of bleeding can be increased when Naftopidil is combined with Phenprocoumon.Approved, Investigational
PhentolamineThe risk or severity of hypotension can be increased when Phentolamine is combined with Naftopidil.Approved
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Naftopidil is combined with Phenyl aminosalicylate.Approved
PhenylbutazoneThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Naftopidil.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Naftopidil.Approved
PicotamideNaftopidil may increase the antiplatelet activities of Picotamide.Experimental
PinacidilPinacidil may increase the hypotensive activities of Naftopidil.Approved
PindololNaftopidil may increase the hypotensive activities of Pindolol.Approved, Investigational
PipecuroniumNaftopidil may increase the neuromuscular blocking activities of Pipecuronium.Approved
PirlindolePirlindole may increase the hypotensive activities of Naftopidil.Approved
PiroxicamThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Pirprofen.Experimental
PitolisantThe serum concentration of Naftopidil can be decreased when it is combined with Pitolisant.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Naftopidil.Withdrawn
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Naftopidil.Approved
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Naftopidil.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Naftopidil.Approved, Investigational
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Naftopidil.Approved
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Naftopidil.Approved, Vet Approved
PolythiazidePolythiazide may increase the hypotensive activities of Naftopidil.Approved
PosaconazoleThe metabolism of Naftopidil can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Naftopidil.Approved, Investigational
Potassium CitrateThe risk or severity of bleeding can be increased when Naftopidil is combined with Potassium Citrate.Approved, Investigational, Vet Approved
PractololNaftopidil may increase the hypotensive activities of Practolol.Approved
PranoprofenThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Pranoprofen.Experimental, Investigational
PrasugrelPrasugrel may increase the antiplatelet activities of Naftopidil.Approved
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Naftopidil.Approved
PrimidoneThe metabolism of Naftopidil can be increased when combined with Primidone.Approved, Vet Approved
ProglumetacinThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Proglumetacin.Experimental
PromazineThe risk or severity of hypotension can be increased when Promazine is combined with Naftopidil.Approved, Vet Approved
PropacetamolThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Propacetamol.Approved, Investigational
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Naftopidil.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Naftopidil.Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Naftopidil.Approved, Investigational
PropranololNaftopidil may increase the hypotensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Proquazone.Experimental
Protein CNaftopidil may increase the anticoagulant activities of Protein C.Approved
Protein S humanThe risk or severity of bleeding can be increased when Naftopidil is combined with Protein S human.Approved
ProtocatechualdehydeThe risk or severity of bleeding can be increased when Naftopidil is combined with Protocatechualdehyde.Approved
PrucaloprideThe therapeutic efficacy of Prucalopride can be decreased when used in combination with Naftopidil.Approved
QuetiapineThe risk or severity of hypotension can be increased when Quetiapine is combined with Naftopidil.Approved
QuinaprilQuinapril may increase the hypotensive activities of Naftopidil.Approved, Investigational
QuinaprilatNaftopidil may increase the hypotensive activities of Quinaprilat.Experimental
QuinidineThe risk or severity of hypotension can be increased when Quinidine is combined with Naftopidil.Approved, Investigational
QuinineThe metabolism of Naftopidil can be increased when combined with Quinine.Approved
RamatrobanNaftopidil may increase the antiplatelet activities of Ramatroban.Investigational
RamiprilRamipril may increase the hypotensive activities of Naftopidil.Approved
RamiprilatNaftopidil may increase the hypotensive activities of Ramiprilat.Experimental
RapacuroniumNaftopidil may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Naftopidil.Approved
RavuconazoleThe therapeutic efficacy of Ravuconazole can be increased when used in combination with Naftopidil.Investigational
RelcovaptanNaftopidil may increase the antiplatelet activities of Relcovaptan.Investigational
RemikirenRemikiren may increase the hypotensive activities of Naftopidil.Approved
RescinnamineNaftopidil may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Naftopidil.Approved, Investigational
ResveratrolResveratrol may increase the antiplatelet activities of Naftopidil.Approved, Experimental, Investigational
ReteplaseNaftopidil may increase the anticoagulant activities of Reteplase.Approved, Investigational
ReviparinThe risk or severity of bleeding can be increased when Naftopidil is combined with Reviparin.Approved, Investigational
RidogrelRidogrel may increase the antiplatelet activities of Naftopidil.Approved
RifampicinThe metabolism of Naftopidil can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Naftopidil can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Naftopidil can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Naftopidil can be increased when combined with Rifaximin.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Naftopidil.Approved, Investigational
RimexoloneThe metabolism of Naftopidil can be increased when combined with Rimexolone.Approved
RiociguatNaftopidil may increase the hypotensive activities of Riociguat.Approved
RisperidoneThe risk or severity of hypotension can be increased when Risperidone is combined with Naftopidil.Approved, Investigational
RitanserinRitanserin may increase the antiplatelet activities of Naftopidil.Investigational
RitonavirThe metabolism of Naftopidil can be decreased when combined with Ritonavir.Approved, Investigational
RituximabNaftopidil may increase the hypotensive activities of Rituximab.Approved
RivaroxabanNaftopidil may increase the anticoagulant activities of Rivaroxaban.Approved
RobenacoxibThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Robenacoxib.Experimental, Vet Approved
RocuroniumNaftopidil may increase the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Rofecoxib.Approved, Investigational, Withdrawn
SafinamideSafinamide may increase the hypotensive activities of Naftopidil.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Naftopidil.Withdrawn
SalicylamideThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Naftopidil is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Salsalate.Approved
SaprisartanSaprisartan may increase the hypotensive activities of Naftopidil.Experimental
SaquinavirThe metabolism of Naftopidil can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Sarilumab.Approved, Investigational
SarpogrelateNaftopidil may increase the antiplatelet activities of Sarpogrelate.Investigational
SaruplaseNaftopidil may increase the anticoagulant activities of Saruplase.Experimental
SC-236The therapeutic efficacy of Naftopidil can be decreased when used in combination with SC-236.Experimental, Investigational
SecobarbitalThe metabolism of Naftopidil can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Naftopidil.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the hypotensive activities of Naftopidil.Approved
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Naftopidil.Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Naftopidil.Approved, Investigational
SertralineSertraline may increase the antiplatelet activities of Naftopidil.Approved
SevofluraneSevoflurane may increase the antiplatelet activities of Naftopidil.Approved, Vet Approved
SibutramineSibutramine may increase the antiplatelet activities of Naftopidil.Approved, Illicit, Investigational, Withdrawn
SildenafilSildenafil may increase the antihypertensive activities of Naftopidil.Approved, Investigational
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Naftopidil.Approved
SiltuximabThe serum concentration of Naftopidil can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Naftopidil can be increased when it is combined with Simeprevir.Approved
SitaxentanNaftopidil may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium CitrateThe risk or severity of bleeding can be increased when Naftopidil is combined with Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Naftopidil.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Naftopidil.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Naftopidil.Approved
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Naftopidil.Approved
SpiraprilSpirapril may increase the hypotensive activities of Naftopidil.Approved
St. John's WortThe serum concentration of Naftopidil can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Naftopidil can be increased when it is combined with Stiripentol.Approved
StreptokinaseNaftopidil may increase the anticoagulant activities of Streptokinase.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Naftopidil.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Naftopidil is combined with Sulfasalazine.Approved
SulfinpyrazoneNaftopidil may increase the antiplatelet activities of Sulfinpyrazone.Approved
SulindacThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Sulindac.Approved, Investigational
SulodexideNaftopidil may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SuprofenThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Suxibuzone.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Naftopidil.Approved, Investigational
TalinololTalinolol may increase the hypotensive activities of Naftopidil.Investigational
TalniflumateThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Talniflumate.Approved
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Naftopidil.Approved, Investigational
TegaserodThe therapeutic efficacy of Tegaserod can be decreased when used in combination with Naftopidil.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Naftopidil can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Naftopidil can be decreased when combined with Telithromycin.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Naftopidil.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of Naftopidil.Experimental, Investigational
TenecteplaseNaftopidil may increase the anticoagulant activities of Tenecteplase.Approved
TenidapThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Naftopidil.Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Naftopidil.Approved
TesmilifeneNaftopidil may increase the antiplatelet activities of Tesmilifene.Investigational
TetrahydropalmatineNaftopidil may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheophyllineTheophylline may increase the antihypertensive activities of Naftopidil.Approved
ThiamylalThe metabolism of Naftopidil can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Naftopidil can be increased when combined with Thiopental.Approved, Vet Approved
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Naftopidil.Approved
ThioridazineThe risk or severity of hypotension can be increased when Thioridazine is combined with Naftopidil.Approved, Withdrawn
Tiaprofenic acidThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Tiaprofenic acid.Approved
TicagrelorNaftopidil may increase the antiplatelet activities of Ticagrelor.Approved
TiclopidineTiclopidine may increase the antiplatelet activities of Naftopidil.Approved
TicrynafenTicrynafen may increase the hypotensive activities of Naftopidil.Withdrawn
TimololNaftopidil may increase the hypotensive activities of Timolol.Approved
TinoridineThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Tinoridine.Investigational
TinzaparinNaftopidil may increase the anticoagulant activities of Tinzaparin.Approved
TioclomarolThe risk or severity of bleeding can be increased when Naftopidil is combined with Tioclomarol.Experimental
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Naftopidil.Approved
TipranavirTipranavir may increase the antiplatelet activities of Naftopidil.Approved, Investigational
TirofibanTirofiban may increase the antiplatelet activities of Naftopidil.Approved
TocilizumabThe serum concentration of Naftopidil can be decreased when it is combined with Tocilizumab.Approved
TocopherylquinoneNaftopidil may increase the hypotensive activities of Tocopherylquinone.Experimental, Investigational
TolazolineThe risk or severity of hypotension can be increased when Tolazoline is combined with Naftopidil.Approved, Vet Approved
Tolfenamic AcidThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
TolmetinThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Tolmetin.Approved
TolonidineNaftopidil may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Naftopidil.Approved
TorasemideTorasemide may increase the hypotensive activities of Naftopidil.Approved
TositumomabThe risk or severity of adverse effects can be increased when Naftopidil is combined with Tositumomab.Approved, Investigational
TrandolaprilTrandolapril may increase the hypotensive activities of Naftopidil.Approved
TranilastTranilast may increase the antiplatelet activities of Naftopidil.Approved, Investigational
TranylcypromineTranylcypromine may increase the hypotensive activities of Naftopidil.Approved, Investigational
TrapidilTrapidil may increase the antiplatelet activities of Naftopidil.Approved
TravoprostTravoprost may increase the hypotensive activities of Naftopidil.Approved
TrazodoneThe risk or severity of hypotension can be increased when Trazodone is combined with Naftopidil.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Naftopidil.Approved, Investigational
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Naftopidil.Approved, Vet Approved
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Naftopidil.Approved, Investigational
TriflusalTriflusal may increase the antiplatelet activities of Naftopidil.Approved, Investigational
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Naftopidil.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Naftopidil.Approved, Investigational
TrimipramineThe risk or severity of hypotension can be increased when Trimipramine is combined with Naftopidil.Approved
Trolamine salicylateThe risk or severity of adverse effects can be increased when Naftopidil is combined with Trolamine salicylate.Approved
TroleandomycinThe metabolism of Naftopidil can be decreased when combined with Troleandomycin.Approved
TroxerutinThe risk or severity of bleeding can be increased when Naftopidil is combined with Troxerutin.Investigational
TubocurarineNaftopidil may increase the neuromuscular blocking activities of Tubocurarine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Naftopidil.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Naftopidil.Approved, Investigational
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Naftopidil.Investigational
UrokinaseNaftopidil may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanValsartan may increase the hypotensive activities of Naftopidil.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Naftopidil.Approved
VecuroniumNaftopidil may increase the neuromuscular blocking activities of Vecuronium.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Naftopidil.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Naftopidil.Approved
VerapamilThe risk or severity of hypotension can be increased when Verapamil is combined with Naftopidil.Approved
VincamineNaftopidil may increase the hypotensive activities of Vincamine.Experimental
Vitamin EVitamin E may increase the antiplatelet activities of Naftopidil.Approved, Nutraceutical, Vet Approved
VorapaxarVorapaxar may increase the antiplatelet activities of Naftopidil.Approved
VoriconazoleThe metabolism of Naftopidil can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinThe risk or severity of bleeding can be increased when Naftopidil is combined with Warfarin.Approved
XimelagatranThe risk or severity of bleeding can be increased when Naftopidil is combined with Ximelagatran.Approved, Investigational, Withdrawn
XipamideNaftopidil may increase the hypotensive activities of Xipamide.Experimental
YohimbineYohimbine may decrease the antihypertensive activities of Naftopidil.Approved, Investigational, Vet Approved
ZaltoprofenThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ZimelidineZimelidine may increase the antiplatelet activities of Naftopidil.Withdrawn
ZiprasidoneThe risk or severity of hypotension can be increased when Ziprasidone is combined with Naftopidil.Approved
ZofenoprilNaftopidil may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Zomepirac.Withdrawn
ZuclopenthixolThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Naftopidil.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
4418
PubChem Substance
347828396
ChemSpider
4265
BindingDB
50773
ChEBI
31891
ChEMBL
CHEMBL142635
Wikipedia
Naftopidil

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceHealthy Volunteers1
3CompletedTreatmentDisorder of Urinary Stent1
3CompletedTreatmentUreter Stones1
3Unknown StatusTreatmentHyperplasia1
4CompletedTreatmentLower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia1
4Unknown StatusTreatmentRenal Stones / Ureter Calculi1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0699 mg/mLALOGPS
logP3.65ALOGPS
logP3.77ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)14.08ChemAxon
pKa (Strongest Basic)7.35ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area45.17 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity115.96 m3·mol-1ChemAxon
Polarizability44.37 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-0940000000-0343a26091ec3a7f543c
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-0849000000-feac1b69e7ec5e9d12d5
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-1940000000-2c5b43ec0ae8e30b33df

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
Phenylpiperazines
Alternative Parents
N-arylpiperazines / Naphthalenes / Methoxyanilines / Aminophenyl ethers / Phenoxy compounds / Methoxybenzenes / Dialkylarylamines / Anisoles / N-alkylpiperazines / Alkyl aryl ethers
show 6 more
Substituents
N-arylpiperazine / Phenylpiperazine / Naphthalene / Aminophenyl ether / Methoxyaniline / Phenoxy compound / Anisole / Phenol ether / Methoxybenzene / Aniline or substituted anilines
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Uesawa Y, Takeuchi T, Mohri K: Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17. [PubMed:22039822]

Drug created on October 20, 2016 15:20 / Updated on August 02, 2018 06:33